Lynx1 Capital Management LP C4 Therapeutics, Inc. Transaction History
Lynx1 Capital Management LP
- $338 Million
- Q2 2025
A detailed history of Lynx1 Capital Management LP transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Lynx1 Capital Management LP holds 7,098,133 shares of CCCC stock, worth $15.9 Million. This represents 3.01% of its overall portfolio holdings.
Number of Shares
7,098,133
Previous 7,098,133
-0.0%
Holding current value
$15.9 Million
Previous $11.4 Million
10.63%
% of portfolio
3.01%
Previous 4.2%
Shares
7 transactions
Others Institutions Holding CCCC
# of Institutions
104Shares Held
57.2MCall Options Held
15.2KPut Options Held
0-
Wasatch Advisors Inc Salt Lake City, UT7.42MShares$16.6 Million0.06% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT6.98MShares$15.6 Million0.77% of portfolio
-
Orbimed Advisors LLC San Diego, CA6.83MShares$15.3 Million0.35% of portfolio
-
Morgan Stanley New York, NY4.75MShares$10.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$10.2 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $110M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...